Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcabene - MetaVia

Next Previous
X
Search
Drug Profile

Gemcabene - MetaVia

Alternative Names: CI-1027; Gemcabene calcium; PD 0072953; PD 072953

Latest Information Update: 27 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Emory University; MetaVia; Pfizer
  • Class Antihyperlipidaemics; Antihypertensives; Antirheumatics; Caproates; Hepatoprotectants; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors; Apolipoprotein C-III inhibitors; C-reactive protein inhibitors; CCR2 receptor antagonists; CCR5 receptor antagonists; Lipoprotein A inhibitors; Peroxisome proliferator-activated receptor agonists; Sulfatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I COVID 2019 infections
  • Suspended Hypercholesterolaemia; Hyperlipoproteinaemia; Hypertension; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Osteoarthritis

Most Recent Events

  • 18 Nov 2024 NeuroBo Pharmaceuticals is now called MetaVia
  • 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Monotherapy) in Unknown (PO)
  • 25 Apr 2023 Gemcabene - NeuroBo Pharmaceuticals is available for licensing as of 25 Apr 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/1638287/000155837023005127/nrbo-20221231x10k.htm

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top